Open Scanner

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Cytokinetics Inc

CYTK
Current price
33.89 USD +0.24 USD (+0.71%)
Last closed 33.57 USD
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 3 291 659 264 USD
Yield for 12 month -11.10 %
Week
Month
Year
CYTK
21.11.2021 - 28.11.2021

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure; and reldesemtiv, a skeletal muscle troponin activator, which is in Phase III clinical trial to treat amyotrophic lateral sclerosis and spinal muscular atrophy. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated has a strategic alliance with Astellas Pharma Inc. The company was incorporated in 1997 and is headquartered in South San Francisco, California. Address: 350 Oyster Point Boulevard, South San Francisco, CA, United States, 94080

Analytics

WallStreet Target Price

60.89 USD

P/E ratio

Dividend Yield

1.46 %

Current Year

+94 588 000 USD

Last Year

+70 428 000 USD

Current Quarter

+378 000 USD

Last Quarter

+867 000 USD

Current Year

-146 225 000 USD

Last Year

-89 510 000 USD

Current Quarter

-82 154 000 USD

Last Quarter

-82 327 000 USD

Key Figures CYTK

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -488 601 984 USD
Operating Margin TTM -32345.24 %
PE Ratio
Return On Assets TTM -34.12 %
PEG Ratio -0.42
Return On Equity TTM -572.15 %
Wall Street Target Price 60.89 USD
Revenue TTM 7 815 000 USD
Book Value -4.56 USD
Revenue Per Share TTM 0.082 USD
Dividend Share
Quarterly Revenue Growth YOY -85 %
Dividend Yield 1.46 %
Gross Profit TTM -146 225 000 USD
Earnings Share -5.55 USD
Diluted Eps TTM -5.55 USD
Most Recent Quarter III 2023
Quarterly Earnings Growth YOY
Profit Margin

Dividend Analytics CYTK

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History CYTK

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield 1.46 %
Last Split Factor 1:6
Payout Ratio
Last Split Date 25.06.2013
Dividend Date

Stock Valuation CYTK

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue 447.4691
Price Sales TTM 421.1976
Enterprise Value EBITDA -7.5587
Price Book MRQ 31.8985

Financials CYTK

1 year
3 years
5 years
10 years
Results 2019 Dynamics

Technical indicators CYTK

For 52 weeks

25.98 USD 47.49 USD
50 Day MA 32.38 USD
Shares Short Prior Month 14 134 117
200 Day MA 35.11 USD
Short Ratio 8.38
Shares Short 13 692 150
Short Percent 23.57 %